Virtu Financial’s Cardiol Therapeutics CRDL Stock Holding History

Virtu Financial’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32K	Buy	+23,917	New	+$24.5K	﹤0.01%	1344
2025 Q4	–	Sell	-144,062	Closed	-$154K	–	1764
2025 Q3	$154K	Buy	+144,062	New	+$175K	0.01%	964
2025 Q2	–	Sell	-16,038	Closed	-$16K	–	1559
2025 Q1	$16K	Sell	16,038 -31,993	-67%	-$39.3K	﹤0.01%	1132
2024 Q4	$61K	Buy	+48,031	New	+$81K	﹤0.01%	1123
2022 Q1	–	Sell	-14,812	Closed	-$27K	–	1581
2021 Q4	$27K	Sell	14,812 -61,007	-80%	-$168K	﹤0.01%	1471
2021 Q3	$315K	Buy	+75,819	New	+$275K	0.03%	691

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial's CRDL Position: Q1 2026 in Review

Virtu Financial opened a new position in Cardiol Therapeutics (CRDL) in Q1 2026: 23,917 shares worth $32K. The stake represents ﹤0.01% of the portfolio and ranks #1344 among its holdings. This is a return to the name: Virtu Financial previously reported a position in CRDL as recently as Q3 2025.

Virtu Financial first reported a position in CRDL in Q3 2021 and has held it in 6 quarters since. The position peaked at $315K in Q3 2021. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

Virtu Financial held 23,917 shares of Cardiol Therapeutics worth $32K as of Q1 2026.
Cardiol Therapeutics was a new Virtu Financial position in Q1 2026.
Cardiol Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q1 2026, its #1344 holding.
Virtu Financial first reported a position in Cardiol Therapeutics in Q3 2021 and has held it in 6 quarters since.
Virtu Financial's Cardiol Therapeutics position peaked at $315K in Q3 2021.
47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.